A post hoc Holter ECG analysis of olodaterol and formoterol in moderate-to-very-severe COPD
S Andreas, U Bothner, A de la Hoz, I Kloer… - … Journal of Chronic …, 2020 - Taylor & Francis
Background Patients with chronic obstructive pulmonary disease (COPD) are at risk of
developing cardiac arrhythmias and elevated heart rate. A theoretical mechanistic …
developing cardiac arrhythmias and elevated heart rate. A theoretical mechanistic …
[引用][C] The 24-hour FEV1 time profile of olodaterol once daily (QD) via Respimat® and formoterol twice daily (BID) via Aerolizer® in patients with COPD: results from …
G Feldman, JA Bernstein, A Hamilton, C Nivens… - Chest, 2013 - journal.chestnet.org
PURPOSE: To determine the 24-hour lung-function profile of olodaterol QD in patients with
GOLD 2-4 COPD. METHODS: In two replicate, randomized, double-blind, placebo …
GOLD 2-4 COPD. METHODS: In two replicate, randomized, double-blind, placebo …
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis
L McGarvey, A Koch, P Sachs, A Hamilton, K Tetzlaff… - 2013 - Eur Respiratory Soc
Background: The novel LABA olodaterol (O) has an acceptable safety profile in clinical
studies of≤ 4 weeks (wks). Objective: To evaluate the long-term safety of O QD in patients …
studies of≤ 4 weeks (wks). Objective: To evaluate the long-term safety of O QD in patients …
No influence on cardiac arrhythmia or heart rate from long-term treatment with tiotropium/olodaterol versus monocomponents by holter ECG analysis in patients with …
S Andreas, U Bothner, A de la Hoz, I Kloer… - … Journal of Chronic …, 2020 - Taylor & Francis
Background Patients with chronic obstructive pulmonary disease (COPD) and
cardiovascular comorbidities may have an increased risk of medication-related cardiac …
cardiovascular comorbidities may have an increased risk of medication-related cardiac …
Efficacy of olodaterol once daily (QD) via Respimat in GOLD 2/3 COPD patients not receiving background therapy: pooled data from 48-week studies
G Ferguson, P Sachs, A Hamilton, K Tetzlaff… - Chest, 2013 - journal.chestnet.org
PURPOSE: The efficacy of olodaterol 5 µg QD versus placebo has been demonstrated in a
broad COPD population with moderate to very severe disease receiving background of …
broad COPD population with moderate to very severe disease receiving background of …
[HTML][HTML] Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients
S Andreas, U Bothner, M Trampisch, M Haensel… - Pulmonary …, 2018 - Elsevier
Background Cardiovascular comorbidities are common in chronic obstructive pulmonary
disease (COPD), and elevated heart rate reflects increased cardiovascular risk over time …
disease (COPD), and elevated heart rate reflects increased cardiovascular risk over time …
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2 …
A Koch, H Watz, MR Maleki-Yazdi, U Bothner… - NPJ Primary Care …, 2017 - nature.com
This analysis provides a comprehensive clinical assessment of the long-term safety of the
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies
A Koch, P Paggiaro, A Hamilton, L Hart, L Korducki… - 2013 - Eur Respiratory Soc
Background: The novel LABA olodaterol (O) has 24-h bronchodilator activity. Objective: To
evaluate the symptomatic benefit of O QD in patients (pts) with GOLD 2-4 COPD. Methods: In …
evaluate the symptomatic benefit of O QD in patients (pts) with GOLD 2-4 COPD. Methods: In …
Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists
C Rebordosa, DK Farkas, J Montonen… - … and Drug Safety, 2022 - Wiley Online Library
Purpose We examined the effect of olodaterol on the risk of myocardial ischaemia, cardiac
arrhythmia, and all‐cause mortality compared with use of other long‐acting beta2‐agonists …
arrhythmia, and all‐cause mortality compared with use of other long‐acting beta2‐agonists …
24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD
JA Van Noord, JJ Smeets, BM Drenth, J Rascher… - Pulmonary …, 2011 - Elsevier
BACKGROUND: Current guidelines recommend long-acting bronchodilators as
maintenance therapy in COPD when symptoms are not adequately controlled with short …
maintenance therapy in COPD when symptoms are not adequately controlled with short …